Quarterly report pursuant to Section 13 or 15(d)

Business, Presentation and Recent Accounting Pronouncements (Details)

v3.23.3
Business, Presentation and Recent Accounting Pronouncements (Details)
3 Months Ended 9 Months Ended
Jun. 06, 2023
USD ($)
Sep. 27, 2022
shares
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
shares
Sep. 26, 2022
shares
Sep. 23, 2022
shares
Subsidiary, Sale of Stock [Line Items]                  
Reverse stock split ratio   0.025              
Common stock, shares authorized (in shares) | shares     50,000,000   50,000,000   50,000,000   50,000,000
Number of fractional shares issued | shares   0              
Common stock outstanding (in shares) | shares   1,079,045 7,689,240   7,689,240   1,796,472 43,163,123  
Cash and cash equivalents     $ 5,400,498   $ 5,400,498   $ 5,964,556    
Accumulated deficit     (144,708,249)   (144,708,249)   (134,462,959)    
Net proceeds $ 5,600,000                
Equity line of credit (up to)     9,600,000   9,600,000        
In-Process R&D Impairment     1,904,314 $ 0 1,904,314 $ 0      
Incurred expenses to related party vendor         130,000        
In-Process R&D                  
Subsidiary, Sale of Stock [Line Items]                  
In-Process R&D     $ 8,695,100 $ 10,600,000 $ 8,695,100 $ 10,600,000 $ 10,599,414    
Common Stock                  
Subsidiary, Sale of Stock [Line Items]                  
Net proceeds $ 5,600,000